Duke University Medical Center is conducting a study to confirm the safety and efficacy of the investigational drug obeticholic acid (also known as OCA or INT-747) in patients with primary biliary cirrhosis (PBC).

The word “investigational” means the study drug, OCA, is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA).

Eligibility Criteria

To participate in this study, you must be an adult who meets the following criteria:

• Have been diagnosed with primary biliary cirrhosis (PBC)
• Screening laboratory values, test, and physical exam within acceptable ranges

Duration

Your participation in this study may range from one year to six years depending on your decision to participate in the long-term safety extension portion of the study.

Visit www.PBC-Study.com for additional information.

For more information, contact Loranda Ross at 919-681-2941 or 866-704-4673.